38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

Supportive Care in Cancer ◽

10.1007/s00520-005-0782-y ◽

2005 ◽

Vol 13 (10) ◽

pp. 797-805 ◽

Cited By ~ 48

Author(s):

F. Hilpert ◽

A. Stähle ◽

O. Tomé ◽

A. Burges ◽

D. Rossner ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Study Group ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Cancer Study Group ◽

Randomized Phase Ii ◽

A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer.

10.1200/jco.2011.29.15_suppl.5010 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5010-5010

Author(s):

I. B. Vergote ◽

P. Harter ◽

N. Kovalenko ◽

T. Bauknecht ◽

K. Mansouri ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

Investigational New Drugs ◽

10.1007/s10637-010-9538-8 ◽

2010 ◽

Vol 30 (2) ◽

pp. 681-687 ◽

Cited By ~ 28

Author(s):

Katalin Boér ◽

István Láng ◽

Antonio Llombart-Cussac ◽

Inger Andreasson ◽

Guillermo L. Vivanco ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Second Line ◽

Double Blind ◽

Double Blind Placebo ◽

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70319-1 ◽

2007 ◽

Vol 2007 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

First Line ◽

Cancer Study ◽

Cancer Study Group ◽

Intergroup Trial ◽

Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group.

10.1200/jco.2011.29.15_suppl.e14007 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14007-e14007 ◽

Cited By ~ 1

Author(s):

T. Matsui ◽

T. Kono ◽

T. Hata ◽

Y. Munemoto ◽

M. Fukunaga ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Neuroprotective Effects ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

Sequential gemcitabine–carboplatin followed by paclitaxel–carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.043 ◽

2006 ◽

Vol 101 (1) ◽

pp. 114-119 ◽

Cited By ~ 4

Author(s):

Johanna U. Mäenpää ◽

Seija E. Grénman ◽

Jyrki T. Jalkanen ◽

Tapio A. Kuoppala ◽

Arto O. Leminen ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2767-y ◽

2015 ◽

Vol 76 (1) ◽

pp. 97-103 ◽

Cited By ~ 34

Author(s):

Chu Matsuda ◽

Yoshinori Munemoto ◽

Hideyuki Mishima ◽

Naoki Nagata ◽

Mitsuru Oshiro ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Cancer Chemotherapy ◽

Oral Mucositis ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737186538.793572794 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Front Line ◽

Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6)

10.1200/jco.2004.22.14_suppl.5016 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5016-5016

Author(s):

S. Loibl ◽

A. Du Bois ◽

J. Pfisterer ◽

J. Huober ◽

H.-J. Lueck ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group

A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer.

10.1200/jco.2010.28.15_suppl.tps257 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS257-TPS257 ◽

Cited By ~ 4

Author(s):

J. D. Hainsworth ◽

T. M. Numnum ◽

G. G. Rao

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽